EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Kidney disease after hematopoietic stem cell transplant—treatment standard

Yu Zhang, Weiwei Fu, Xianghua Huang iD

Nephrology Dialysis Transplantation · 26.11.2025 · 40 (12) · 2268-2279

DOI: 10.1093/ndt/gfaf139 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 17.07.2025. Verfasst von Yu Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Kidney Diseases, Graft vs Host Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic stem cell transplant (HSCT) is a well-established procedure for malignant and nonmalignant conditions. Despite its therapeutic benefits, kidney disease remains a common complication that significantly affects patient outcomes. Kidney injury post-HSCT manifests as acute kidney injury and chronic kidney disease, with multifactorial causes such as conditioning regimens, nephrotoxic drugs, graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TA-TMA). Accurate diagnosis often requires a kidney biopsy due to overlapping risk factors and complex clinical presentations. This review summarizes current diagnostic and therapeutic standards, highlights advance in biomarkers and pathophysiology, and discusses targeted therapies such as rituximab for GVHD-related glomerulopathies and eculizumab for TA-TMA. Supportive care, immunomodulation, and early intervention remain critical. For patients progressing to end stage renal disease, renal replacement therapy and kidney transplantation post-HSCT offer viable long-term options. Despite these advances, challenges persist, including the need for noninvasive diagnostic tools and standardized management protocols. Future research into pathophysiology, biomarkers, and targeted therapies holds promise for improving outcomes in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationKidney DiseasesGraft vs Host DiseaseHumansPrognosis

Stichwörter der Autor:innen

hematopoietic stem cell transplantkidney diseasepathophysiologyprognosistreatment

Autor:innen und Institutionen

  • National Clinical Research Center for Kidney Diseases, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China.
  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affliated Hospital of Medical School, Nanjing University, Nanjing, China.

ORCID-Profile: Xianghua Huang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Fu, W., & Huang, X. (2025). Kidney disease after hematopoietic stem cell transplant—treatment standard. Nephrology Dialysis Transplantation, 40(12), 2268-2279. https://doi.org/10.1093/ndt/gfaf139

Vancouver

Zhang Y, Fu W, Huang X. Kidney disease after hematopoietic stem cell transplant—treatment standard. Nephrology Dialysis Transplantation. 2025;40(12):2268-2279. doi:10.1093/ndt/gfaf139

BibTeX
@article{Zhang2025,
  author = {Zhang, Yu and Fu, Weiwei and Huang, Xianghua},
  title = {Kidney disease after hematopoietic stem cell transplant—treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {12},
  pages = {2268--2279},
  doi = {10.1093/ndt/gfaf139}
}
Kostenlos starten →